What an educational piece of work! It will be exciting to see if this approach can be used as a preventative measure against immune-related #endocrinocrinopathies! #irAEs #Oncoendocrinology

It is always bittersweet to see our hematology/oncology fellows graduate. Sweet because of how wonderful it is to see them develop and go on to practice, and bitter because they have become part of our family and we will miss them. NYU Grossman Long Island School of Medicine

It's the end of an incredible and fulfilling journey. Forever grateful to my amazing patients, supportive mentors, and the extraordinary teams at NYU Langone Health, NYULISOM_HemOnc, and Perlmutter Cancer Center at NYU Langone Health for three years of growth and invaluable experiences.

Across two continents, our multicenter study examines chronic #irAEs post #CPI #AntiPD1 treatment. 🌍🌎 #ImmunoOncology

FDA approved capivasertib with fulvestrant for HR+ HER2-neg locally advanced/metastatic breast cancer with PIK3CA/AKT1/PTEN alterations following progression on endocrine-based regimen or recurrence on completing adjuvant therapy fda.gov/drugs/resource… Click to #OCENewsBurst ⬆️

In this study, the endocrine-sensitive disease rate (ESDR) following 6 months of neoadjuvant fulvestrant or anastrozole plus fulvestrant was 22.8% and 20.5%, respectively; neither was significantly higher than the 18.7% ESDR with anastrozole alone. ja.ma/48JWqS0

Much needed international multidisciplinary consensus on integrating #radiotherapy with new systemic treatments for #breastcancer sciencedirect.com/science/articl…

Jeffrey S. Weber, the ⭐ 2023 Pedro J. Romero Service to #JITC Award recipient ⭐, will be presenting a 3-year update from the KEYNOTE-942 trial later today at #ASCO24. Read more from him and colleagues in this popular #JITC research: bit.ly/4c41nX1

Spent a lovely evening with fellows and young faculty discussing breast cancer abstracts at #ASCO24 Always fun to meet new colleagues from around the country Targeted Oncology OncLive.com Yael Simons, MD Arjan Gower, MD, MS Taiwo Adesoye MD MPH Malinda T West Azka Ali, MD Arya Roy Faisal Fa’ak

We mourn the loss of pharmacologist Dr. V. Craig Jordan, who discovered Selective Estrogen Receptor Modulators (SERMs) and developed breakthrough breast cancer treatments. Read more about his legacy: bit.ly/3XlxJIx #EndCancer

Most viewed in the last 7 days from JAMA Oncology: Does bilateral mastectomy for treatment of unilateral breast cancer reduce the 20-year risk of breast cancer mortality? ja.ma/3Sy7bQW